Enfusion (NYSE:ENFN) Hits New 1-Year High – Here’s What Happened

Enfusion, Inc. (NYSE:ENFN)’s stock price reached a new 52-week high during mid-day trading on Thursday . The company traded as high as $11.80 and last traded at $11.38, with a volume of 160693 shares changing hands. The stock had previously closed at $11.07.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. William Blair reaffirmed a “market perform” rating on shares of Enfusion in a research report on Monday, January 13th. Piper Sandler boosted their target price on shares of Enfusion from $10.00 to $11.50 and gave the company a “neutral” rating in a research note on Monday, December 23rd. Finally, Stifel Nicolaus upped their target price on shares of Enfusion from $11.00 to $13.00 and gave the stock a “buy” rating in a research report on Wednesday, December 18th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $10.50.

Enfusion Trading Up 3.0 %

The business’s 50-day simple moving average is $10.79 and its 200 day simple moving average is $9.61. The company has a market capitalization of $1.47 billion, a P/E ratio of 284.95, a P/E/G ratio of 1.81 and a beta of 0.96.

Insider Activity

In related news, CEO Oleg Movchan sold 2,771 shares of the business’s stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $10.13, for a total value of $28,070.23. Following the sale, the chief executive officer now directly owns 526,702 shares in the company, valued at $5,335,491.26. The trade was a 0.52 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Bradley Herring sold 4,134 shares of the company’s stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $10.13, for a total value of $41,877.42. Following the sale, the chief financial officer now directly owns 266,369 shares of the company’s stock, valued at approximately $2,698,317.97. This represents a 1.53 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 57,367 shares of company stock worth $591,335 over the last 90 days. 36.44% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Centiva Capital LP lifted its stake in shares of Enfusion by 5.0% in the 3rd quarter. Centiva Capital LP now owns 25,596 shares of the company’s stock valued at $243,000 after purchasing an additional 1,227 shares during the last quarter. Harbor Capital Advisors Inc. lifted its position in shares of Enfusion by 12.4% in the third quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company’s stock worth $113,000 after buying an additional 1,315 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Enfusion by 5.9% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,070 shares of the company’s stock worth $289,000 after acquiring an additional 1,567 shares in the last quarter. Rhumbline Advisers increased its holdings in shares of Enfusion by 3.0% during the 4th quarter. Rhumbline Advisers now owns 62,464 shares of the company’s stock valued at $643,000 after acquiring an additional 1,796 shares during the last quarter. Finally, Azora Capital LP raised its stake in shares of Enfusion by 6.8% in the 3rd quarter. Azora Capital LP now owns 29,827 shares of the company’s stock valued at $283,000 after acquiring an additional 1,890 shares in the last quarter. Hedge funds and other institutional investors own 81.05% of the company’s stock.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.